Stacking Safety Checker
Select two or more peptides to check their interaction profile. See which combinations are commonly used, which require caution, and which to avoid, with plain-language explanations of the underlying mechanism.
Peptide Interaction Checker
Select 2 or more peptides to check their interaction profile. All selected pairs are evaluated and sorted by severity, most critical first.
Select 2 or more peptides to see interaction data
Peptide and Medication Conflict Checker
Type a medication you currently take to see which peptides may conflict with it and why. Always discuss any combination with your prescribing physician before making changes.
Enter a medication name to check for peptide conflicts
Common Safe Stacks
These combinations are frequently used together in research contexts and are generally considered compatible. Individual response always varies, baseline labs and physician oversight are still recommended.
BPC-157 + TB-500
Tissue Repair & Recovery
BPC-157 targets localized tissue healing via growth factor upregulation and nitric oxide modulation. TB-500 promotes systemic regeneration through actin polymerization and angiogenesis. The two pathways are complementary, one of the most studied peptide combinations in research literature.
Ipamorelin + CJC-1295
GH Optimization & Body Composition
Ipamorelin (GHRP) and CJC-1295 (GHRH analog) bind to different receptors and work synergistically, CJC-1295 amplifies the GH pulse window while Ipamorelin triggers the release. Produces a larger, more sustained GH output than either alone without significantly blunting cortisol or prolactin response.
Epithalon + NAD+
Longevity & Cellular Health
Epithalon acts on telomere maintenance and epigenetic regulation via the pineal gland. NAD+ supports mitochondrial function and cellular energy through sirtuin and PARP pathways. Completely distinct mechanisms, no known conflicts. A well-regarded longevity-focused combination.
BPC-157 + Thymosin Alpha-1
Immune Support & Tissue Repair
BPC-157 reduces local inflammation and supports tissue healing; Thymosin Alpha-1 modulates immune activity through thymic pathways. Complementary mechanisms with no known adverse interaction. Often explored in chronic inflammation or post-illness recovery contexts.
BPC-157 + NAD+
Systemic Recovery
BPC-157 promotes tissue repair through growth factor signaling; NAD+ supports the cellular energy systems that repair processes depend on. Additive rather than competing pathways. No known adverse interaction, common in performance and recovery protocols.
Combinations to Avoid
These pairings carry documented or theoretically significant risks. Some are absolute contraindications; others require specialist physician oversight before any consideration.
Semaglutide + Tirzepatide
Both are GLP-1 receptor agonists. Combining them adds no benefit and significantly increases risk of severe gastrointestinal side effects (nausea, vomiting, gastroparesis), hypoglycemia, and pancreatitis. There is no clinical or research rationale for stacking two GLP-1 agonists simultaneously.
Mechanism: Redundant GLP-1 receptor agonism, additive toxicity, zero additive benefit
Thymosin Alpha-1 + Immunosuppressants
Thymosin Alpha-1 is a thymic peptide that stimulates immune activity. Combining it with immunosuppressant medications (tacrolimus, cyclosporine, mycophenolate) directly opposes their mechanism. In transplant patients, this interaction could trigger organ rejection or an immune crisis.
Mechanism: Opposing immune modulation, direct pharmacological contraindication
GH Secretagogues + Exogenous Insulin
GH secretagogues (Ipamorelin, CJC-1295, Sermorelin) promote insulin resistance as a direct consequence of GH elevation. In individuals taking exogenous insulin, this creates unpredictable and potentially dangerous blood glucose swings. Hypoglycemia risk is significant. Requires endocrinologist oversight at minimum, may be contraindicated depending on clinical context.
Mechanism: GH-driven insulin resistance + exogenous insulin = unpredictable glycemic instability
Triple GH Stack (3+ Secretagogues Simultaneously)
Combining multiple GH secretagogues simultaneously, e.g. Ipamorelin + CJC-1295 + Sermorelin, risks supraphysiologic IGF-1 elevation, insulin resistance, water retention, joint pain, and GH receptor desensitization over time. No established research supports triple GH stacking. Use one pairing (e.g. Ipamorelin + CJC-1295), get an IGF-1 baseline, and monitor before adding anything further.
Mechanism: Excessive GH axis stimulation, risk of supraphysiologic IGF-1 and downstream effects
GH Secretagogues + Active or Recent Cancer History
GH and IGF-1 elevation is associated with potential mitogenic signaling, the same pathways that promote tissue growth can theoretically promote tumor cell proliferation in IGF-1-sensitive cancers (certain breast, prostate, and colorectal cancers). Individuals with relevant cancer history must obtain oncologist clearance before any GH-axis peptide use.
Mechanism: IGF-1-driven mitogenic signaling, context-dependent, not universal contraindication
Ready to Build Your Protocol?
Use the Peptide Finder to identify which categories may fit your goals, then use the Protocol Builder to map out your schedule.